TECHNO MARKET - By Ouest Valorisation

L'accompagnement sur-mesure de vos projets d'innovation

Notre mission :
Proposer aux entreprises des ressources d'innovation attractives issues de plus de 160 laboratoires et 7200 chercheurs.

New Onco Immunotherapeutic approach for IL34 dependant cancer

Osteosarcoma is a type of bone cancer that often affects children and young adults. Interleukin-34 (IL-34) is a cytokine produced by cancer cells that promotes the progression of osteosarcoma by increasing tissue vascularization, stimulating the recruitment of macrophages and their differentiation towards the M2 phenotype. IL-34 is also involved in immunosuppression and chemoresistance.

IL-34 appears as a pro-metastatic regulator in osteosarcoma, and its inhibition could be a potential therapeutic strategy to block tumor progression.

Researchers have developed an antibody that binds to IL-34 with high affinity and is capable of inhibiting IL-34-mediated cell proliferation and intracellular signal transduction. Using an anti-IL34 antibody, they observed a complete blockage of tumor progression in a syngeneic model of osteosarcoma. According to a study published in PubMed, overexpression of IL-34 was associated with osteosarcoma progression and increased neo-angiogenesis. The study also demonstrated that IL-34 stimulated endothelial cell proliferation and vascular marrow formation. IL-34 is expressed by osteosarcoma cells, is regulated by TNF-α, IL-1β, and contributes to osteosarcoma growth by increasing neoangiogenesis and M2 macrophage recruitment . Another study published in PMC documented the overexpression of IL-34 in several cancers, including osteosarcoma, and its role in promoting tumor progression and the metastatic process. the use of an anti-IL34 antibody could be a promising therapeutic approach to block tumor progression in osteosarcoma.

Cette solution est faite pour vous si vous êtes :

- Une entreprise qui souhaite utiliser la solution
- Une entreprise qui souhaite commercialiser la solution
- Une entreprise qui souhaite adapter la solution à son besoin

Nature de l'offre :

- Prevention of tumor growth and metastatic
- Possible combination with conventional chemotherapy
- No side effect

Domaines d'application :

- Antinéoplasiques
- agents immunomodulants

Votre contact :
Hervé LE DEIT
Hervé LE DEIT
06 18 70 35 04
herve.le-deit@ouest-valorisation.fr
DV n°2439 - Anti IL-34 antibodies